Amgen Presents AMG 420 Phase 1 Data in Myeloma
05 June 2019 - 10:26PM
Dow Jones News
By Michael Dabaie
Amgen Inc. (AMGN) Wednesday presented data from Phase 1 studies
evaluating investigational bispecific T cell engager molecules,
including updated investigational AMG 420 results in patients with
relapsed and/or refractory multiple myeloma.
As of the latest readout, AMG 420 induced clinical responses in
13 of 42 patients across the dosing cohorts, Amgen said. The
overall response rate at 400 ug/d was 70%, with median duration of
response of nine months.
Serious adverse events were reported in 19 patients, or 45%.
Sixteen required hospitalization and four had prolonged
hospitalization, Amgen said. No grade 3 or 4 central nervous system
toxicities were observed, the company said.
Of the six patients that achieved a minimal residual
disease-negative complete response, five were treated at the 400
ug/d dose. In addition, at the 400 ug/d dose, one patient achieved
a very good partial response, and one achieved a partial response,
Amgen said.
Amgen presented the data at the 55th Annual Meeting of the
American Society of Clinical Oncology in Chicago.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 05, 2019 08:11 ET (12:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2024 to May 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From May 2023 to May 2024